ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 07 avr. 2025 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

ISIN code: FR0010425595

DateNombre total d’actions

composant le capital social		Nombre total de droits de vote
31/03/2025100 290 07889 046 759



Pour de plus amples informations sur Cellectis, veuillez contacter :        

Contacts média :        

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Contact pour les relations avec les investisseurs :        

Arthur Stril, Chief Financial Officer & Chief Business Officer, +1 (347) 809 5980,



Pièce jointe



EN
07/04/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis présente une approche non virale d’édition du génome et des ...

Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025 NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires et géniques, dévoile aujourd’hui une approche non virale d’insertion de transgènes via TALEN® pour faire progresser les thérapies cellulaires et géniques, et des avancées dans l’édition génétique avec les TALE base editor...

3h / 48m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation ...

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, th...

3h / 57m 1 EN
Julian Dobrovolschi
  • Julian Dobrovolschi
ENX EURONEXT NV
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
04/11/25 April 11, 2025 1 EN
Julian Dobrovolschi
  • Julian Dobrovolschi
ENX EURONEXT NV
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
04/11/25 April 11, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
ALCLS CELLECTIS SA

Cellectis : Cellectis: the reference player in allogeneic CAR-T cells

Cellectis is the French specialist in allogeneic CAR-T cells, now mainly developed in cancer treatment. Its first CAR-T in partnership with Servier and Allogene is currently in the pivot phase in first-line diffuse B-cell lymphoma, while its most advanced own CAR-T candidate is expected to enter into the pivot phase II in H2 this year in acute lymphoblastic leukaemia. Bolstered by a recent deal with AstraZeneca, which acquired a stake in the company (+44%), we are initiating coverage of the stoc...

04/10/25 April 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch